Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
22 Cards in this Set
- Front
- Back
|
Signaling inhibitors, PRE IL2 Production. Inhibit Calcineurin and block IL2 Production.
|
Cyclosporine and Tacrolimus/FK506 Signaling inhibitors.
|
|
|
Maintenance therapy post organ transplant
|
Cyclosporine and Tacrolimus/FK506 Signaling inhibitors.
|
|
|
Nephrotoxicity, hepatotoxicity, neurotoxicity
|
Cyclosporine and Tacrolimus/FK506 Signaling inhibitors.
|
|
|
AA: Hyperlipidemia
|
Sirolimus
|
|
|
Signaling inhibitor, POST IL2 production. Inhibits mTOR
|
Sirolimus
|
|
|
Synthetic corticosteroid. Suppresses cytokine (IL1) production.
PRE-IL2 production |
Prednisone
|
|
|
AA: Insomnia, hypomania, ulcers
|
Prednisone
|
|
|
Proliferation inhibitors.
POST IL2 production. (Alkylating agent). AA: Myelosuppression |
Cyclophosphamide
|
|
|
Proliferation inhibitors. POST IL2 production.
(Folate mimicking anti-metabolite). AA: Myelosuppression |
Methotrexate
|
|
|
Proliferation inhibitors. POST IL2 production.
(anti-metabolite) AA: Myelosuppression |
Mycophenolate Mofetil
|
|
|
Mechanism: Chimeric (humanized) monoclonal antibody against CD20 B-cell antigen
|
Rituximab
|
|
|
Clinical Use: Relapsed, indolent B-cell lymphomas, Multiple Sclerosis, and combined with methotrexate to treat Rheumatoid Arthritis
|
Rituximab
|
|
|
Mechanism: Chimeric (humanized) monoclonal anti TNF-alpha antibody
|
Infliximab
|
|
|
Clinical Use:Crohn’s disease.
Also used combined with methotrexate to treat Rheumatoid Arthritis |
Infliximab
|
|
|
Mechanism: Chimeric (humanized) monoclonal anti-IL6 receptor antibody
|
Tocilizumab
|
|
|
Clinical Use: Rheumatoid Arthritis
|
Tocilizumab
|
|
|
Mechanism: Anti- IL2 receptor antibody. Blocks activation of Il2 receptor, hence blocking T-cell activation
|
Daclizumab
|
|
|
Clinical Use: Acute transplant rejection
|
Daclizumab
|
|
|
Mechanism: Binds to CD-3 on the Tcell. Inhibiting Tcell function
|
Muromonab-CD3/ OKT-3
|
|
|
Clinical Use:Acute transplant rejection
|
Muromonab-CD3/ OKT-3
|
|
|
Mechanism: Lyses the (Rh+) erythrocytes of the baby before mother mounts an immune response
|
RhD immune globulin/ RHOGAM
|
|
|
Clinical Use: RhD immune globulin/ RHOGAM Lyses the (Rh+) erythrocytes of the baby before mother mounts an immune response Given to a Rh- mother within 72 hours of giving birth to a Rh+ baby. Protects future Rh+ baby from hemolytic disease
|
RhD immune globulin/ RHOGAM
|
